SPPI - Spectrum Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.33
-0.32 (-1.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close19.65
Open19.71
Bid16.01 x 3200
Ask19.33 x 900
Day's Range18.90 - 19.84
52 Week Range7.12 - 23.50
Volume5,422,232
Avg. Volume1,749,649
Market Cap1.992B
Beta2.50
PE Ratio (TTM)N/A
EPS (TTM)-0.92
Earnings DateMar 7, 2017 - Mar 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-12-18
1y Target Est29.25
Trade prices are not sourced from all markets
  • Spectrum Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
    Zacks5 days ago

    Spectrum Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

    Spectrum Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

  • Why Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) Is A Financially Healthy Company
    Simply Wall St.6 days ago

    Why Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) Is A Financially Healthy Company

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Spectrum Pharmaceuticals Inc (NASDAQ:SPPI), with a market capitalization of US$2.06B, rarely draw their attention from the investingRead More...

  • ACCESSWIRE17 days ago

    Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Tesaro

    NEW YORK, NY / ACCESSWIRE / June 7, 2018 / U.S. equities closed in the green on Wednesday, as bond yields rose pushing financial sector higher. The Dow Jones Industrial Average jumped 1.40 percent to close ...

  • Business Wire25 days ago

    Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 Global Healthcare Conference on June 6th

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at the Jefferies 2018 Global Healthcare Conference being held at the Grand Hyatt in New York. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.

  • ACCESSWIRElast month

    Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).

  • Why Spectrum Pharmaceuticals, Inc. Is Up Big Today
    Motley Foollast month

    Why Spectrum Pharmaceuticals, Inc. Is Up Big Today

    Shares jumped after the company shared new details from an important phase 3 study. Here's what investors need to know.

  • Business Wirelast month

    CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract

    Fourth paragraph, first sentence of release dated May 16, 2018, should read: “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes one Phase 2 and two Phase 3 clinical studies involving approximately 800 patients” (instead of “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes two Phase 3 clinical studies involving approximately 800 patients”). ROLONTIS is a novel long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing myelosuppressive cytotoxic chemotherapy.

  • Business Wirelast month

    Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced detailed results from ADVANCE, a Phase 3 trial of ROLONTIS, demonstrating that it was non-inferior to pegfilgrastim in the reduction of duration of severe neutropenia (DSN) in all four cycles of the study. ROLONTIS is a novel long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing myelosuppressive cytotoxic chemotherapy. “These data expand our understanding of the clinical profile of eflapegrastim and help establish it as a possible supportive care treatment option for the multitude of patients undergoing chemotherapy,” said Lee Schwartzberg, M.D., FACP, lead investigator, professor of medicine and division chief, hematology oncology, University of Tennessee Health Science Center, and executive director, UT/West Cancer Center.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16th

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company’s business strategy and commercial and development-stage programs will be given at the Bank of America Merrill Lynch 2018 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. A live webcast of Spectrum’s presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SPPI earnings conference call or presentation 3-May-18 8:30pm GMT

    Q1 2018 Spectrum Pharmaceuticals Inc Earnings Call

  • ACCESSWIRE2 months ago

    Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib

    LONDON, UK / ACCESSWIRE / May 07, 2018 / If you want access to our free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SPPI as the Company's latest news hit the wire. On May 03, 2018, the Company announced that it has inked an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to exon 20 and certain methods of use of poziotinib. Active-Investors.com is currently working on the research report for Arbutus Biopharma Corporation (NASDAQ: ABUS), which also belongs to the Healthcare sector as the Company Spectrum Pharma.

  • Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1
    Zacks2 months ago

    Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1

    Spectrum (SPPI) reports narrower-than-expected loss in the first quarter and also beat revenues. Rolontis successful in phase III study.

  • Associated Press2 months ago

    Spectrum Pharma: 1Q Earnings Snapshot

    On a per-share basis, the Henderson, Nevada-based company said it had a loss of 16 cents. Losses, adjusted for one-time gains and costs, came to 15 cents per share. The biotechnology company posted revenue ...

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update

    Spectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period ended March 31, 2018.

  • Investopedia2 months ago

    Top 4 Small-Cap Stocks for 2018

    Small-cap stocks are considered riskier than large caps or even mid caps. Of course, this means that smaller stocks have greater potential to make profits for investors. This does not mean that you should buy risky stocks randomly.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to certain methods of use of poziotinib. “We have been aggressively pursuing the potential of exon 20 mutations and treatment with poziotinib since the inception of our relationship with MD Anderson, but we’ve both only begun to scratch the surface of the science and poziotinib’s potential as a targeted treatment for various solid tumors,” said Joe Turgeon, president and CEO of Spectrum Pharmaceuticals.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher Scientific

    Spectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it has entered into an agreement with Thermo Fisher Scientific to leverage the Oncomine™ Dx Target Test as a companion diagnostic for Spectrum’s novel pan-HER inhibitor, poziotinib, which is in development for the ...

  • Can These Top-Performing Biotech Stocks Keep Climbing?
    Motley Fool2 months ago

    Can These Top-Performing Biotech Stocks Keep Climbing?

    Over the past year, these two biotech stocks outperformed nearly all their peers. Can they keep it going?

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Announces Corporate Governance Enhancements and Board Changes

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that it has taken a number of actions designed to further enhance its corporate governance practices. On March 23, 2018, the board approved amendments to Spectrum’s bylaws and shareholder rights plan to establish proxy access rights, implement a majority voting standard and rescind the stockholder rights plan, commonly referred to as a poison pill. Additionally, the nominating and corporate governance committee has recommended one new candidate, Dr. Bernice Welles, to replace Dr. Rajesh Shrotriya and Dr. Luigi Lenaz, and will reduce the size of the board to eight members.

  • Business Wire2 months ago

    Company Profile for SPECTRUM PHARMACEUTICALS

    Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the company.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Announces First Quarter 2018 Financial Results Teleconference and Webcast

    Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the first quarter 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, May 3, 2018 ...

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Announces Publication of Poziotinib Data in Nature Medicine

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced a publication entitled, “Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer.” The publication appears in the April 23, 2018 online issue at https://www.nature.com/articles/s41591-018-0007-9 and will be published in a future print issue of Nature Medicine. “We are honored to have data from poziotinib published in this prestigious journal,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. For cancer patients that have exon 20 mutations, physicians have very few options.

  • Business Wire2 months ago

    Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago

    Spectrum Pharmaceuticals , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced a poster presentation of data from preclinical and clinical studies evaluating poziotinib in HER2 exon 20 mutations in non-small cell lung cancer and summarizing a dataset of the prevalence of HER2 exon 20 across solid tumors ...

  • Market Exclusive2 months ago

    Here’s What Happened Last Week In Biotech

    It was a busy week last week in the biotechnology space, with a whole host of companies putting out updates on their respective operations (primarily rooted in development pipelines) and these updates subsequently injecting a considerable amount of volatility into the markets on their release. Here’s a look at some of the biggest movers, what […] The post Here’s What Happened Last Week In Biotech appeared first on Market Exclusive.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool2 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these red-hot biotech stocks keep the momentum going?